Profile data is unavailable for this security.
About the company
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
- Revenue in TWD (TTM)3.43bn
- Net income in TWD403.00m
- Incorporated1997
- Employees1.01k
- LocationScinoPharm Taiwan LtdNo. 1, Nan-Ke 8th RoadTainan Science Industrial ParkShan-Hua DistrictTAINAN 741TaiwanTWN
- Phone+886 65052888
- Fax+886 65052897
- Websitehttps://www.scinopharm.com.tw/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adimmune Corp | 1.66bn | -607.92m | 9.51bn | 564.00 | -- | 1.86 | -- | 5.74 | -1.44 | -1.44 | 3.93 | 11.92 | 0.1848 | 1.25 | 4.04 | -- | -8.27 | 0.6867 | -10.19 | 0.7739 | 27.82 | 30.11 | -44.75 | 3.04 | 1.99 | -24.75 | 0.3284 | 32.80 | -20.72 | 16.77 | -319.91 | -- | 38.05 | -- |
| Formosa Laboratories Inc | 4.69bn | 255.94m | 10.94bn | 480.00 | 43.10 | 1.46 | 18.23 | 2.33 | 2.11 | 2.11 | 38.90 | 62.49 | 0.3479 | 1.49 | 4.42 | -- | 0.7067 | 2.68 | 0.9689 | 3.61 | 44.30 | 35.40 | 2.03 | 8.75 | 1.18 | 0.8922 | 0.3155 | 27.38 | 15.80 | 10.16 | -69.16 | -6.52 | -11.60 | 32.22 |
| Standard Chem & Pharm Co Ltd | 6.71bn | 847.58m | 11.37bn | 1.13k | 13.42 | 1.92 | 7.10 | 1.69 | 4.74 | 4.74 | 37.50 | 33.05 | 0.6066 | 2.39 | 6.00 | -- | 10.98 | 9.68 | 20.02 | 17.61 | 43.81 | 43.75 | 18.10 | 17.02 | 1.93 | -- | 0.0795 | 60.34 | 6.64 | 11.80 | 2.39 | 17.40 | 29.97 | 12.47 |
| SCI Pharmtech Inc | 1.41bn | 484.24m | 11.47bn | 241.00 | 24.05 | 2.12 | 16.36 | 8.12 | 3.99 | 3.99 | 13.98 | 45.36 | 0.2211 | 1.82 | 4.61 | -- | 7.58 | 6.90 | 8.56 | 8.26 | 27.11 | 38.18 | 34.26 | 19.85 | 1.68 | 9.22 | 0.1692 | 42.38 | 33.83 | -9.10 | -4.55 | -8.00 | 44.67 | -16.35 |
| YungShin Global Holding Corp | 7.44bn | 1.05bn | 14.47bn | 1.57k | 13.74 | 1.96 | 10.18 | 1.95 | 3.95 | 3.95 | 27.91 | 27.66 | 0.5953 | 1.47 | 5.51 | -- | 9.10 | 6.64 | 13.58 | 10.20 | 43.28 | 45.11 | 15.29 | 10.45 | 1.35 | -- | 0.1034 | 70.94 | -3.88 | -1.33 | -1.40 | 3.34 | -29.00 | 0.893 |
| ScinoPharm Taiwan Ltd | 3.43bn | 403.00m | 18.42bn | 1.01k | 45.83 | 1.78 | 21.07 | 5.37 | 0.5084 | 0.5084 | 4.33 | 13.12 | 0.2871 | 1.27 | 6.63 | -- | 3.37 | 2.33 | 3.69 | 2.51 | 38.89 | 41.09 | 11.76 | 9.10 | 5.00 | -- | 0.0592 | 109.25 | -2.39 | -2.00 | -18.73 | -8.31 | 16.90 | -9.35 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Oct 2024 | 10.58m | 1.34% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 8.24m | 1.04% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 3.27m | 0.41% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 3.05m | 0.39% |
| Schroder Investment Management (Hong Kong) Ltd.as of 30 Jun 2024 | 1.77m | 0.22% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 951.32k | 0.12% |
| Vanguard Fiduciary Trust Co.as of 31 Aug 2024 | 354.81k | 0.05% |
| TIAA-CREF Investment Management LLCas of 31 Aug 2024 | 209.00k | 0.03% |
| Mellon Investments Corp.as of 03 Oct 2024 | 209.00k | 0.03% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 171.00k | 0.02% |
